Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 25  

 
   Table of Contents      
LETTER TO EDITOR
Year : 2017  |  Volume : 16  |  Issue : 4  |  Page : 338-339

68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography: How much specific it is?


Department of Nuclear Medicine & PET/CT, Medanta - The Medicity, Gurugram, Haryana, India

Date of Web Publication22-Sep-2017

Correspondence Address:
Manas Kumar Sahoo
Associate Consultant, Department of Nuclear Medicine & PET/CT, Medanta - The Medicity, Gurugram - 122 001, Haryana
India
Login to access the Email id


DOI: 10.4103/wjnm.WJNM_2_17

PMID: 29033688

Rights and Permissions

How to cite this article:
Sahoo MK. 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography: How much specific it is?. World J Nucl Med 2017;16:338-9

How to cite this URL:
Sahoo MK. 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography: How much specific it is?. World J Nucl Med [serial online] 2017 [cited 2021 Jan 26];16:338-9. Available from: http://www.wjnm.org/text.asp?2017/16/4/338/215482

Dear Editor,

I went through the Review article, “68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (68 Ga-PSMA PET/CT) for prostate cancer imaging: A narrative literature review” by Oliveira et al.[1] The manuscript is well written and well appreciated as it covers a narrow review on 68Ga-PSMA PET/CT which has become a popular choice in the management of prostate cancer.

As there is increase in concern and ongoing trials of therapy-related with positive findings on the metastatic work up in 68Ga-PSMA PET/CT, it is very much essential and ethical while interpreting the prostate-specific membrane antigen (PSMA) uptake. For this reason, I felt this review should also pay little attention regarding the false-positive uptakes of PSMA whose number is increasing gradually as more and more the modality is being explored.

Chang et al. demonstrated the strong reaction of five anti-PSMA antibodies including 7E11 in the in the neovasculature of wide variety of malignant neoplasms including renal cell carcinoma (RCC), transitional cell carcinoma, testicular embryonal carcinoma, colonic adenocarcinoma, neuroendocrine carcinomas, glioblastoma multiforme, malignant melanoma, pancreatic duct carcinoma, nonsmall cell lung carcinoma, soft tissue sarcomas, and breast carcinoma. Even though prostatic adenocarcinoma tumor cells showed PSMA positivity in all cases in the study, neovasculature of prostatic adenocarcinoma showed PSMA positivity only in 2 of 12 cases.[2]

Apparently, the tumor neoangiogenesis is the mechanism attributed to increased Ga-PSMA uptake in the tumor sites in nonprostatic malignancies. Recently,68 Ga-PSMA uptake has been demonstrated in multiple myeloma. In addition, PSMA uptake has been described in papillary carcinoma of thyroid, gastrointestinal stromal tumor.[3]

Synchronous metastatic inguinal, pelvic, and retroperitoneal lymph node metastases have been proved showing PSMA uptake in case of penile and prostate cancer. PSMA expression was seen in tumor vessels and may explain the 68Ga-PSMA-PET/CT positivity of inguinal nodes involved in squamous cell carcinoma.[4] In addition, in another reported case, retroperitoneal lymph node and thyroid tissues showed metastases from RCC, whereas the pelvic lymph node exhibited metastasis from prostate cancer in 68Ga-PSMA PET/CT.

As 68Ga-PSMA PET/CT has become a popular gateway for theranostic with Lu-PSMA, it becomes very much essential to understand the pattern and pathophysiology of benign uptakes of PSMA as it can wrongly categorize benign nodes to be of metastatic node which may end up in wrong upstaging tumor burden assessment, thus putting unnecessary radiation burden on the patient apart from all other socioeconomic burden.

In 2 cases of Ga-PSMA PET/CT in prostate cancer patients, symmetrical bilateral involvement of mediastinal and hilar lymph nodes showed biopsy-proven sarcoidosis.[5] Subacute cortical cerebral infarct, follicular thyroid adenoma, and benign senile seminal vesicle amyloidosis in a prostate cancer patient showing focal uptake on PSMA PET/CT have also been reported. Furthermore, in another case, a 65-year-old male with left-sided pelvic pain on evaluation was found to have histopathologically proven Paget's disease of pelvis showing increased PSMA uptake.[6]

Even though imaging using Anti-PSMA agents tagged with radionuclides are considered tumor specific, these reports warrant caution in reporting lesions showing increased uptake as metastases in patients with prostatic adenocarcinoma. Pathological confirmation of suspected lesions or 18fluid fluorodeoxyglucose PET/CT should be done to rule out synchronous or metachronous malignancy which can show similar uptake to avoid mismanagement in such patients. Although it is a potential drawback of the modality, at the same time, it also gives a scope for innovation of theranostic for many nonprostatic cancers, and further trials should be encouraged like in multiple myeloma and thyroid cancer.

As the lists of benign uptakes are also in the rise, there should be high degree of suspicion and pathological confirmation in isolated pelvic/retroperitoneal lymph nodes or seminal vesicle uptake so that they should not be over treated with Lu-PSMA without undergoing histological confirmation. Further studies including larger trials can only validate its specificity in prostate cancer or else it may be a tool to guide sites for pathological confirmation.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Oliveira JM, Gomes C, Faria DB, Vieira TS, Silva FA, Vale J, et al. 68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review. World J Nucl Med 2017;16:3-7.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.  Back to cited text no. 2
[PUBMED]    
3.
Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT. Clin Nucl Med 2017;42:200-202.  Back to cited text no. 3
[PUBMED]    
4.
Froehner M, Kuithan F, Zöphel K, Heberling U, Laniado M, Wirth MP. Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. Urology 2017;101:e5-6.  Back to cited text no. 4
    
5.
Dias AH, Holm Vendelbo M, Bouchelouche K. Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis. Clin Nucl Med 2017;42:e175-6.  Back to cited text no. 5
[PUBMED]    
6.
Sasikumar A, Joy A, Nanabala R, Pillai MR, TA. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med 2016;41:e454-5.  Back to cited text no. 6
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1291    
    Printed25    
    Emailed0    
    PDF Downloaded158    
    Comments [Add]    

Recommend this journal